Financial Performance & Growth - Artivion achieved approximately $400 million in revenue and around $70 million in EBITDA for FY24[5] - The company is driving sustained double-digit revenue growth and expects 2x+ EBITDA growth[14] - Full year 2025 revenue guidance is between $439 million and $445 million, representing a year-over-year constant currency growth of 13-14%[73] - Full year 2025 adjusted EBITDA is expected to be between $88 million and $91 million, a year-over-year growth of 24-28%[76] - Net debt leverage is expected to decrease to less than 20x by year-end 2025, with net debt at 18x as of September 30, 2025[69] Business Segments & Market Opportunities - Preservation Services (CryoValve® SG) generated $98 million in revenue in 2024, holding the 1 market position with a 65% share in a $150 million global TAM[17] - Surgical Sealant (BioGlue) had $74 million in revenue in 2024, holding the 2 market position with a 28% share in a $260 million global TAM[17] - On-X aortic valve is uniquely positioned for younger AVR patients, creating a new $100 million U S market opportunity[24] - The company is focused on more complex, less competitive stent graft segments, with a 16% 3-year CAGR[38] - AMDS addresses a $150 million addressable market opportunity and is expected to receive PMA approval by mid-2026[41,46] Clinical Data & Product Performance - On-X aortic heart valve post-approval study (PAS) shows a 66% reduction in major events and an 87% reduction in major bleeding compared to the PROACT IDE study[20] - TRIOMPHE US IDE Trial for Endospan NEXUS® demonstrates a 63% reduction in major adverse event (MAE) rate compared to the reference performance goal[53] - AMDS use significantly lowers 30-day Major Adverse Events (MAEs) compared to hemiarch control, with 269% MAEs in PERSEVERE vs 580% in the Hemiarch Reference Cohort[47]